Promising Findings for R/R Large B-Cell Lymphoma – Glofitama and Epcoritamab Show Curative Potential

Martin Hutchings, senior consultant at Rigshospitalet, Copenhagen, elaborates on studies presented at EHA23, ASCO23, and in Lugano, providing sufficient follow-up results on patients with relapsed/refractory (R/R) large B-cell lymphoma who received glofitamab or epcoritamab. Based on these findings, there is compelling evidence to suggest that these CD3 × CD20 bispecific antibodies possess curative potential.